Cibus, Inc.
Cibus develops gene-edited plant traits for seed companies, which can incorporate the traits into their seed products. Its core technology platform, the Rapid Trait Development System, supports the Trait Machine process, which edits customer seed genetics. Cibus focuses primarily on productivity traits, including herbicide-tolerance traits for rice, and earns money by licensing traits and receiving royalties or license fees tied to seed sales or acres planted. It also develops sustainable ingredients, including lauric oils and biofragrance products made using yeast genetics and fermentation, with some work funded or supported by partners. Rice herbicide tolerance is Cibus’ priority program. Its other crop programs include canola, soybean, wheat and alfalfa, as well as platforms in cassava, flax, peanut, potato and sugar beet. Cibus is consolidating its core operations to San Diego, California.
No enriched coverage for $CBUS in the last 7 days.
No SEC Form 4 filings for $CBUS in the last 30 days.
See all $CBUS insider activity →Cibus Real Estate reported 10% NOI growth, completing EUR 12.5M acquisitions in Finland. Portfolio value rose 0.5%, yield remained at 6.4%. Refinanced SEK 700M bond, reducing margin by 148 bps. 94% of leases are CPI-linked, occupancy at 96%. ESG targets achieved ahead of schedule. EPRA NRV per share data awaited.
Cibus (CBUS) reported Q2 2026 revenue of $1 million, up from $900,000 in Q2 2025, with a net loss of $22.1 million. The company highlighted cost reductions and growth in its sustainable ingredients program. Management discussed a shift to a royalty-based model, targeting rice and other crops, and expects to need additional funding in early 2027. Cash and cash equivalents were $20.4 million as of June 30, 2026.
Cibus (NASDAQ:CBUS) reported cash and cash equivalents of $20.4 million as of June 30. Management said cash burn declined 19% sequentially and 31% year over year, with existing cash expected to fund operations and capex into early Q1 2027. Guidance updates include shifting an initial Latin America rice launch to 2028 and targeting biofragrance revenue of $20 million to $40 million when commercialized.
Recent CBUS coverage spans earnings, financial news and regulation.
Cibus Real Estate reported 10% NOI growth, completing EUR 12.5M acquisitions in Finland. Portfolio value rose 0.5%, yield remained at 6.4%. Refinanced SEK 700M bond, reducing margin by 148 bps. 94% of leases are CPI-linked, occupancy at 96%. ESG targets achieved ahead of schedule. EPRA NRV per share data awaited.
Earnings show modest revenue growth but continued losses; cash runway limited, indicating potential need for financing.
The call highlights slower rice commercialization timing but improved regulatory clarity and a progressing commercial ramp, shifting the risk balance toward execution and partner orders.
New regulatory clarity plus expanded partner scope and updated launch timing can re-rate commercialization probability and near-term cash burn trajectory.
EU regulatory classification could reduce compliance friction and broaden adoption of Cibus-licensed traits in Europe.
AlphAI scores every news story that mentions CBUS with an AI model for sentiment and relevance, and aggregates insider trades from Cibus, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Cibus Real Estate reported 10% NOI growth, completing EUR 12.5M acquisitions in Finland. Portfolio value rose 0.5%, yield remained at 6.4%. Refinanced SEK 700M bond, reducing margin by 148 bps. 94% of leases are CPI-linked, occupancy at 96%. ESG targets achieved ahead of schedule. EPRA NRV per share data awaited.
Cibus (CBUS) reported Q2 2026 revenue of $1 million, up from $900,000 in Q2 2025, with a net loss of $22.1 million. The company highlighted cost reductions and growth in its sustainable ingredients program. Management discussed a shift to a royalty-based model, targeting rice and other crops, and expects to need additional funding in early 2027. Cash and cash equivalents were $20.4 million as of June 30, 2026.
Cibus (NASDAQ:CBUS) reported cash and cash equivalents of $20.4 million as of June 30. Management said cash burn declined 19% sequentially and 31% year over year, with existing cash expected to fund operations and capex into early Q1 2027. Guidance updates include shifting an initial Latin America rice launch to 2028 and targeting biofragrance revenue of $20 million to $40 million when commercialized.
Cibus, Inc. (CBUS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Cibus Reports Second Quarter Financial Results and Provides Business Update Commercialization execution advances in Rice and Sustainable Ingredients United States and European Union now aligned on generally treating crops with no added foreign DNA as conventionally bred Quarterly
Cibus, Inc. (NASDAQ:CBUS) said an EU decision will treat certain improved crops without added foreign DNA as conventionally bred rather than transgenic GMOs. Cibus said its gene-edited traits that improve disease resistance and input efficiency may qualify for a non-GMO fast lane. The company also announced CEO leadership changes, with Craig Wichner appointed CEO.
Cibus, Inc. (Nasdaq: CBUS) said the EU has adopted rules treating crops improved without adding foreign DNA as conventionally bred, not as transgenic GMOs. The company said this validates its gene-editing approach developed over nearly 25 years and could help European farmers adopt traits such as disease resistance and reduced chemical use. Cibus expects some traits to qualify under the EU “Category 1” fast lane.
Cibus, Inc. (CBUS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. cbus-20260608 0001705843 FALSE 0001705843 2026-06-08 2026-06-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________ FORM 8-K ______________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Dat
Cibus, Inc. (Nasdaq: CBUS) said Craig Wichner, a board member since Nov. 2025, was appointed CEO as part of its succession plan. Peter Beetham, previously interim CEO, will remain President and COO. Both resigned from the board. Cibus said Beetham helped raise over $62 million in new investment during his interim tenure.
Cibus (CBUS) delivered earnings and revenue surprises of -7.32% and -43.58%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Cibus Inc. ( NASDAQ:CBUS ) surged 23.81% to $1.82 in the pre-market trading session on Wednesday, following President Donald Trump's latest trade escalation with China. Check out the current price of CBUS stock here. According to Benzinga Pro data, Cibus closed at $1.47 on Tuesday.
